MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck
Carcinoma Patients Treated With Intensity-modulated
Radiotherapy

J 2019

MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy

AHMAD, Parwez; Jiří ŠÁNA; Marek SLÁVIK; Dominik GURÍN; Lenka RADOVÁ et. al.

Základní údaje

Originální název

MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy

Autoři

Vydání

CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2019, 1109-6535

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.280

Kód RIV

RIV/00216224:14740/19:00108511

Organizační jednotka

Středoevropský technologický institut

DOI

https://doi.org/10.21873/cgp.20119

UT WoS

000463451200004

EID Scopus

2-s2.0-85062590666

Klíčová slova anglicky

Head and neck cancer; microRNA; miR-15b-5p; locoregional control; radiotherapy; IMRT

Štítky

14110112, 14110126, 14110812, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 6. 2020 13:07, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. Materials and Methods: A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. Results: We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapsefree survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25 ; 95% CI=0.05-0.78; p<0.016). Conclusion: miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.

Návaznosti

NV15-31627A, projekt VaV

Název: Možnosti molekulárně řízené radikální radioterapie nebo radiochemoterapie dle profilu mikroRNA u pacientů se spinocelulárními karcinomy hlavy a krku.

Citovat

AHMAD, Parwez; Jiří ŠÁNA; Marek SLÁVIK; Dominik GURÍN; Lenka RADOVÁ; Natalia Anna GABŁO; Tomáš KAZDA; Pavel SMILEK; Zuzana HORÁKOVÁ; Břetislav GÁL; Markéta HERMANOVÁ; Pavel ŠLAMPA a Ondřej SLABÝ. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. CANCER GENOMICS & PROTEOMICS. ATHENS: INT INST ANTICANCER RESEARCH, 2019, roč. 16, č. 2, s. 139-146. ISSN 1109-6535. Dostupné z: https://doi.org/10.21873/cgp.20119.

@article{1555278,
   author = {Ahmad, Parwez and Šána, Jiří and Slávik, Marek and Gurín, Dominik and Radová, Lenka and Gabło, Natalia Anna and Kazda, Tomáš and Smilek, Pavel and Horáková, Zuzana and Gál, Břetislav and Hermanová, Markéta and Šlampa, Pavel and Slabý, Ondřej},
   article_location = {ATHENS},
   article_number = {2},
   doi = {https://doi.org/10.21873/cgp.20119},
   keywords = {Head and neck cancer; microRNA; miR-15b-5p; locoregional control; radiotherapy; IMRT},
   language = {eng},
   issn = {1109-6535},
   journal = {CANCER GENOMICS & PROTEOMICS},
   title = {MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy},
   url = {http://cgp.iiarjournals.org/content/16/2/139.full.pdf},
   volume = {16},
   year = {2019}
}

TY  - JOUR
ID  - 1555278
AU  - Ahmad, Parwez - Šána, Jiří - Slávik, Marek - Gurín, Dominik - Radová, Lenka - Gabło, Natalia Anna - Kazda, Tomáš - Smilek, Pavel - Horáková, Zuzana - Gál, Břetislav - Hermanová, Markéta - Šlampa, Pavel - Slabý, Ondřej
PY  - 2019
TI  - MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy
JF  - CANCER GENOMICS & PROTEOMICS
VL  - 16
IS  - 2
SP  - 139-146
EP  - 139-146
PB  - INT INST ANTICANCER RESEARCH
SN  - 11096535
KW  - Head and neck cancer
KW  - microRNA
KW  - miR-15b-5p
KW  - locoregional control
KW  - radiotherapy
KW  - IMRT
UR  - http://cgp.iiarjournals.org/content/16/2/139.full.pdf
L2  - http://cgp.iiarjournals.org/content/16/2/139.full.pdf
N2  - Background/Aim: Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. Materials and Methods: A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. Results: We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapsefree survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25 ; 95% CI=0.05-0.78; p<0.016). Conclusion: miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.
ER  -

AHMAD, Parwez; Jiří ŠÁNA; Marek SLÁVIK; Dominik GURÍN; Lenka RADOVÁ; Natalia Anna GABŁO; Tomáš KAZDA; Pavel SMILEK; Zuzana HORÁKOVÁ; Břetislav GÁL; Markéta HERMANOVÁ; Pavel ŠLAMPA a Ondřej SLABÝ. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. \textit{CANCER GENOMICS \&{}amp; PROTEOMICS}. ATHENS: INT INST ANTICANCER RESEARCH, 2019, roč.~16, č.~2, s.~139-146. ISSN~1109-6535. Dostupné z: https://doi.org/10.21873/cgp.20119.

Přehled o publikaci